EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era-Reference-Cited by-同舟云学术

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

Published:2013-11-11 Issue:2 Volume:49 Page:280-286
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Fox C P,Burns D,Parker A N,Peggs K S,Harvey C M,Natarajan S,Marks D I,Jackson B,Chakupurakal G,Dennis M,Lim Z,Cook G,Carpenter B,Pettitt A R,Mathew S,Connelly-Smith L,Yin J A L,Viskaduraki M,Chakraverty R,Orchard K,Shaw B E,Byrne J L,Brookes C,Craddock C F,Chaganti S

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2013170.pdf

Reference30 articles.

1. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925–935.

2. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992–5001.

3. Hale G, Waldmann H . Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998; 91: 3079–3083.

4. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

5. Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG et al. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy 2001; 3: 145–164.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children;Frontiers in Immunology;2024-07-11

2. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation;Frontiers in Immunology;2024-01-11

3. Management of Infections in Stem Cell Transplant Recipients;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation;Annals of Hematology;2023-12-29

5. Virus infections after allogeneic stem cell transplantation in children. Review;EJC Paediatric Oncology;2023-12